Inovio Pharmaceuticals Stock Falls After Pricing Offering

Dow Jones

2025/07/03

By Kelly Cloonan

Shares of Inovio Pharmaceuticals declined after the company disclosed the pricing of an underwritten public offering for shares of its common stock.

The stock fell 38% to $1.33 on Thursday. Shares are down 84% in the past 12 months.

The biotechnology company will offer about 14.3 million common shares for $1.75 apiece.

Underwriters have been granted a 30-day option to purchase up to an additional 2.1 million shares at the public offering price, the company said.

Inovio expects the offering to generate gross proceeds of about $25 million.

The offering is expected to close on July 7, subject to customary closing conditions.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

July 03, 2025 11:47 ET (15:47 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2548838655"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548838655\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548838655?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-03 23:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548838655","market":"sh","top_or_hot":-1,"title":"Inovio Pharmaceuticals Stock Falls After Pricing Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By <a href=\"https://laohu8.com/S/KELYA\">Kelly</a> Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals</a> declined after the company disclosed the pricing of an underwritten public offering for shares of its common stock. \n</p>\n<p>\n  The stock fell 38% to $1.33 on Thursday. Shares are down 84% in the past 12 months. \n</p>\n<p>\n  The biotechnology company will offer about 14.3 million common shares for $1.75 apiece. \n</p>\n<p>\n  Underwriters have been granted a 30-day option to purchase up to an additional 2.1 million shares at the public offering price, the company said. \n</p>\n<p>\n  Inovio expects the offering to generate gross proceeds of about $25 million. \n</p>\n<p>\n  The offering is expected to close on July 7, subject to customary closing conditions. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to <a href=\"https://laohu8.com/S/KELYB\">Kelly</a> Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 03, 2025 11:47 ET (15:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inovio Pharmaceuticals Stock Falls After Pricing Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInovio Pharmaceuticals Stock Falls After Pricing Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-03 23:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By <a href=\"https://laohu8.com/S/KELYA\">Kelly</a> Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals</a> declined after the company disclosed the pricing of an underwritten public offering for shares of its common stock. \n</p>\n<p>\n  The stock fell 38% to $1.33 on Thursday. Shares are down 84% in the past 12 months. \n</p>\n<p>\n  The biotechnology company will offer about 14.3 million common shares for $1.75 apiece. \n</p>\n<p>\n  Underwriters have been granted a 30-day option to purchase up to an additional 2.1 million shares at the public offering price, the company said. \n</p>\n<p>\n  Inovio expects the offering to generate gross proceeds of about $25 million. \n</p>\n<p>\n  The offering is expected to close on July 7, subject to customary closing conditions. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to <a href=\"https://laohu8.com/S/KELYB\">Kelly</a> Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 03, 2025 11:47 ET (15:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2548838655","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548838655","pubTimestamp":1751557620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Inovio Pharmaceuticals declined after the company disclosed the pricing of an underwritten public offering for shares of its common stock.The stock fell 38% to $1.33 on Thursday. Shares are down 84% in the past 12 months.The biotechnology company will offer about 14.3 million common shares for $1.75 apiece.Underwriters have been granted a 30-day option to purchase up to an additional 2.1 million shares at the public offering price, the company said.Inovio expects the offering to generate gross proceeds of about $25 million.The offering is expected to close on July 7, subject to customary closing conditions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","INO":"伊诺维奥制药","BK4583":"猴痘概念","BK4568":"美国抗疫概念"},"translate_title":"Inovio Pharmaceuticals股价在定价发行后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INO":1},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Inovio Pharmaceuticals declined after the company disclosed the pricing of an underwritten public offering for shares of its common stock. \n\n\n  The stock fell 38% to $1.33 on Thursday. Shares are down 84% in the past 12 months. \n\n\n  The biotechnology company will offer about 14.3 million common shares for $1.75 apiece. \n\n\n  Underwriters have been granted a 30-day option to purchase up to an additional 2.1 million shares at the public offering price, the company said. \n\n\n  Inovio expects the offering to generate gross proceeds of about $25 million. \n\n\n  The offering is expected to close on July 7, subject to customary closing conditions. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 03, 2025 11:47 ET (15:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}